{"title":"激素难治性前列腺腺癌模拟基底细胞癌1例报告","authors":"Justin E. Caron, S. Hart, K. Chamie, Huihui Ye","doi":"10.1097/PCR.0000000000000368","DOIUrl":null,"url":null,"abstract":"Abstract Prostate cancer is an androgen-driven malignancy. Patients with late-stage prostate cancer often receive androgen-deprivation therapy to suppress the disease progression. Under the selection pressure, some prostate cancers transform to androgen-independent cancers. Treatment-induced small cell neuroendocrine carcinoma is one of the examples. In the last decade, patients with disseminated prostate cancer frequently received second-generation androgen-deprivation agents, such as abiraterone, enzalutamide, and apalutamide. Those more potent drugs have led to an emergence of a novel type of androgen-independent carcinoma named “double-negative” prostate cancer, which is immunohistochemically negative for both neuroendocrine markers and androgen targets. In this report, we present a typical case of “double-negative” end-stage prostate cancer that morphologically resembled basal cell carcinoma of prostate, basaloid large nest type.","PeriodicalId":72144,"journal":{"name":"AJSP: reviews & reports","volume":"8 1","pages":"109 - 111"},"PeriodicalIF":0.1000,"publicationDate":"2020-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hormone -Refractory Prostatic Adenocarcinoma Mimicking Basal Cell Carcinoma: A Case Report\",\"authors\":\"Justin E. Caron, S. Hart, K. Chamie, Huihui Ye\",\"doi\":\"10.1097/PCR.0000000000000368\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Prostate cancer is an androgen-driven malignancy. Patients with late-stage prostate cancer often receive androgen-deprivation therapy to suppress the disease progression. Under the selection pressure, some prostate cancers transform to androgen-independent cancers. Treatment-induced small cell neuroendocrine carcinoma is one of the examples. In the last decade, patients with disseminated prostate cancer frequently received second-generation androgen-deprivation agents, such as abiraterone, enzalutamide, and apalutamide. Those more potent drugs have led to an emergence of a novel type of androgen-independent carcinoma named “double-negative” prostate cancer, which is immunohistochemically negative for both neuroendocrine markers and androgen targets. In this report, we present a typical case of “double-negative” end-stage prostate cancer that morphologically resembled basal cell carcinoma of prostate, basaloid large nest type.\",\"PeriodicalId\":72144,\"journal\":{\"name\":\"AJSP: reviews & reports\",\"volume\":\"8 1\",\"pages\":\"109 - 111\"},\"PeriodicalIF\":0.1000,\"publicationDate\":\"2020-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AJSP: reviews & reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/PCR.0000000000000368\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AJSP: reviews & reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/PCR.0000000000000368","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PATHOLOGY","Score":null,"Total":0}
Hormone -Refractory Prostatic Adenocarcinoma Mimicking Basal Cell Carcinoma: A Case Report
Abstract Prostate cancer is an androgen-driven malignancy. Patients with late-stage prostate cancer often receive androgen-deprivation therapy to suppress the disease progression. Under the selection pressure, some prostate cancers transform to androgen-independent cancers. Treatment-induced small cell neuroendocrine carcinoma is one of the examples. In the last decade, patients with disseminated prostate cancer frequently received second-generation androgen-deprivation agents, such as abiraterone, enzalutamide, and apalutamide. Those more potent drugs have led to an emergence of a novel type of androgen-independent carcinoma named “double-negative” prostate cancer, which is immunohistochemically negative for both neuroendocrine markers and androgen targets. In this report, we present a typical case of “double-negative” end-stage prostate cancer that morphologically resembled basal cell carcinoma of prostate, basaloid large nest type.